Tepadina

In combination w/ other chemotherapy drugs w/ or w/o total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adults & paed patients; when high dose chemotherapy w/ HPCT support is appropriate for breast cancer in adults & CNS tumours in paed patients.

IV Adult Autologous HPCT (haematological disease) & lymphoma 125-300 mg/m² daily (3.38-8.1 mg/kg daily) as single daily infusion, administered from 2-4 consecutive days before autologous HPCT. Max: 900 mg/m² (24.32 mg/kg). CNS lymphoma 185 mg/m² daily (5 mg/kg daily) as single daily infusion, administered for 2 consecutive days before autologous HPCT. Max: 370 mg/m² (10 mg/kg). Breast cancer 120-250 mg/m² daily (3.24-6.76 mg/kg daily) as single daily infusion, administered from 3-5 consecutive days before autologous HPCT. Max: 800 mg/m² (21.62 mg/kg). Allogeneic HPCT (haematological disease) 185-481 mg/m² daily (5-13 mg/kg daily) divided in 1 or 2 daily infusions, administered from 1-2 consecutive days before allogeneic HPCT. Max: 555 mg/m² (15 mg/kg). Lymphoma 370 mg/m² daily (10 mg/kg daily) divided in 2 daily infusions before allogeneic HPCT. Max: 370 mg/m² (10 mg/kg). Leukaemia 185-370 mg/m² daily (5-10 mg/kg daily) divided in 1 or 2 daily infusions, administered from 1-2 consecutive days before allogeneic HPCT. Max: 555 mg/m² (15 mg/kg). Childn CNS Tumour 200-300 mg/m² daily (8-12 mg/kg daily) as single daily infusion administered for 3 consecutive days before autologous HPCT. Max: 900 mg/m² (36 mg/kg). Allogeneic HPCT (haematological disease) 125-250 mg/m² daily (5-10 mg/kg day) divided in 1 or 2 daily infusions, administered from 1-3 consecutive days before allogeneic HPCT. Max: 375 mg/m² (15 mg/kg). Leukaemia 250 mg/m² daily (10 mg/kg daily) divided in 2 daily infusions, administered before allogeneic HPCT. Max: 250 mg/m² (10 mg/kg). Thalassemia 200-250 mg/m² daily (8-10 mg/kg daily) divided in 2 daily infusions, administered before allogeneic HPCT. Max: 250 mg/m² (10 mg/kg). Refractory cytopenia 125 mg/m² daily (5 mg/kg daily) as single daily infusion, administered for 3 consecutive days before allogeneic HPCT. Max: 375 mg/m² (15 mg/kg). Genetic disease 125-250 mg/m² daily (5-10 mg/kg daily) as single daily infusion or administered for 2 consecutive days before allogeneic HPCT. Max: 250 mg/m² (10 mg/kg). Sickle cell anaemia 250 mg/m² daily (10 mg/kg daily) divided in 2 daily infusions, administered before allogeneic HPCT. Max: 250 mg/m² (10 mg/kg).

Hypersensitivity. Concomitant use w/ yellow fever vaccine, live virus & bacterial vaccines. Pregnancy & lactation.

Cytotoxic Chemotherapy

L01AC01 - thiotepa ; Belongs to the class of alkylating agents, ethylene imines. Used in the treatment of cancer.

POM